Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Big Is The Neurological Disorder Drugs Market Today And What Is Its Future Size?

In recent times, the market size for drugs related to neurological disorders has seen substantial growth. It is projected to rise from $84.6 billion in 2024 to $89.24 billion in 2025, registering a compound annual growth rate (CAGR) of 5.5%. The past growth can be associated with an escalation in animal testing yielding promising outcomes, an uptick in therapeutic treatments, increase in neurological issues, government-led initiatives, and an upsurge in healthcare spending.

Expectations are high for strong growth within the neurological disorder drugs market over the approaching years, with a projected increase to “$110.99 billion by 2029, showcasing a compound annual growth rate (CAGR) of 5.6%. This advancement during this period can be credited to the expansion of tailored therapies and therapeutic options, an increased focus on treatments aimed towards disease modification, digital biomarkers’ growing implementation, and an overall rise in neurological disease incidence. In the forecast period, impactful trends include drug design enhancements, progress in neuroimaging, breakthroughs in genetics research, collaborative efforts and licensure agreements, and the burgeoning field of regenerative medicine.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

What External And Internal Drivers Are Influencing The Neurological Disorder Drugs Market?

The surge in neurological diseases is anticipated to boost the expansion of the neurological disorder drugs market. Neurological disorders are conditions that affect the brain, spinal cord, and nerves due to structural, biochemical, or electrical abnormalities, resulting in various symptoms. The augmentation of neurological diseases is ascribed to the aging global populace along with increased exposure to environmental, metabolic, and lifestyle hazards. Neurological disorder drugs are integral in handling these intricate conditions, providing symptom relief, slowing the course of the illness, and enhancing patient’s long-term prognosis. For example, in September 2024, as per the Australian Institute of Health and Welfare, a governmental agency based in Australia, it’s projected that the number of dementia patients in Australia will more than double from 2023 to 2058, advancing from about 411,100 in 2023 to 849,300 by 2058, with approximately 315,500 men and 533,800 women affected. Consequently, the escalating prevalence of neurological disease is fueling the growth of the neurological disorder drugs market.

How Is The Neurological Disorder Drugs Market Organized By Different Segments?

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

What Current And Upcoming Trends Are Shaping The Neurological Disorder Drugs Market?

Major entities in the neurological disorder drugs market are concentrating on the creation of novel Ocrelizumab drug treatments to boost the effectiveness of therapy, better patient results, and extend treatment choices for those suffering from multiple sclerosis. Used in treating this type of neurological disorder, Ocrelizumab is a monoclonal antibody that has been humanized. To exemplify, in February 2024, Roche Holding AG, a pharmaceutical firm based in Switzerland, introduced Ocrevus (Ocrelizumab), a groundbreaking disease-modifying therapy (DMT) drug to treat multiple sclerosis in India. Ocrevus made history as the first-ever approved DMT for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) based on more than a decade of clinical and real-world evidence. This monoclonal antibody specifically targets CD20-positive B cells which are suspected to be involved in the autoimmune attack on the central nervous system in cases of multiple sclerosis (MS). Ocrevus treats both RRMS and PPMS, positioning it as the first drug to be approved for both disease types. Given intravenously, typically biannually, Ocrevus has demonstrated its effectiveness in diminishing disease activity and slowing down disability progression during clinical trials.

Who Are The Most Influential Companies In The Neurological Disorder Drugs Market?

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Which Region Dominates The Neurological Disorder Drugs Market Today?

North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=17207&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model